Our team is partnered with a major US research institution on the forefront of peptide research. We are focused exclusively on quality verification to bring safety and reliability to the RUO supply chain. Proudly based in New York City.
The peptide supply chain lacks consistent, independent verification. Compounding pharmacies and research groups often rely on supplier-provided COAs with no way to confirm them.
We operate as a fully independent third party — with no financial relationship to peptide manufacturers or suppliers. Every report includes raw data, chromatograms or spectra, and a clear pass/fail summary your team can act on.
The principles that guide every report, every result, and every client relationship.
No financial relationships with peptide suppliers or manufacturers. Your analysis is yours alone.
Every report includes raw data — chromatograms, spectra, instrument parameters — not just a summary.
Methods follow USP monographs and ICH guidelines. Assays are validated; procedures documented.
We work as a long-term quality partner to compounding pharmacies, 503B facilities, and research groups.
3–7 business days typical. Rush options available for time-sensitive lot releases.
Reports are formatted for pharmacy board review, USP compliance, and FDA inspection readiness.
We work with any organization that needs independent analytical verification of peptide materials.
COA verification and lot release support for patient-specific peptide preparations.
Full lot release panels, stability support, and documentation for FDA-registered outsourcing facilities.
Identity and purity characterization for research-use peptide materials requiring third-party documentation.